去甲丙咪嗪氧化表型与哌唑嗪的药代动力学及首剂效应之间缺乏相关性。
Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
作者信息
Lennard M S, McGourty J C, Silas J H
机构信息
University Department of Therapeutics, Royal Hallamshire Hospital, Sheffield.
出版信息
Br J Clin Pharmacol. 1988 Feb;25(2):276-8. doi: 10.1111/j.1365-2125.1988.tb03303.x.
Abstract
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of a single oral dose of prazosin has been studied in eight hypertensive patients (four extensive and four poor metabolisers). No significant differences between the two phenotypes were observed in either the area under the plasma prazosin concentration-time curve, the terminal half-life or the first-dose effect of prazosin.
摘要
在8名高血压患者（4名快代谢者和4名慢代谢者）中研究了异喹胍氧化表型与单次口服哌唑嗪的药代动力学和药效学之间的关系。在血浆哌唑嗪浓度-时间曲线下面积、终末半衰期或哌唑嗪的首剂效应方面，两种表型之间均未观察到显著差异。
相似文献
1
Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.去甲丙咪嗪氧化表型与哌唑嗪的药代动力学及首剂效应之间缺乏相关性。
Br J Clin Pharmacol. 1988 Feb;25(2):276-8. doi: 10.1111/j.1365-2125.1988.tb03303.x.
2
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
3
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
4
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.甲苯磺丁脲代谢与异喹胍氧化表型之间缺乏相关性。
Eur J Clin Pharmacol. 1987;33(4):397-402. doi: 10.1007/BF00637637.
5
Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.安非他明在异喹胍代谢快和代谢慢的人群中的代谢氧化作用。
Eur J Clin Pharmacol. 1982;23(2):147-50. doi: 10.1007/BF00545969.
6
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
7
Timolol metabolism and debrisoquine oxidation polymorphism: a population study.噻吗洛尔代谢与异喹胍氧化多态性：一项群体研究。
Br J Clin Pharmacol. 1989 Apr;27(4):429-34. doi: 10.1111/j.1365-2125.1989.tb05390.x.
8
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
9
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
10
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.美托洛尔代谢与异喹胍氧化多态性——群体与家系研究
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
引用本文的文献
1
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.司巴丁/异喹胍氧化多态性的临床意义
Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732.
本文引用的文献
1
Quantification of prazosin in plasma by high-performance liquid chromatography.
J Chromatogr. 1980 Nov 14;221(1):188-92. doi: 10.1016/s0378-4347(00)81024-5.
2
Oxidation phenotype--a major determinant of metoprolol metabolism and response.氧化表型——美托洛尔代谢及反应的主要决定因素。
N Engl J Med. 1982 Dec 16;307(25):1558-60. doi: 10.1056/NEJM198212163072505.
3
Clinical pharmacokinetics of prazosin.哌唑嗪的临床药代动力学
Clin Pharmacokinet. 1980 Jul-Aug;5(4):365-76. doi: 10.2165/00003088-198005040-00004.
4
Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose.哌唑嗪的临床药理学研究。I：单次给药后的心血管、儿茶酚胺及内分泌变化。
Br J Clin Pharmacol. 1980 Jul;10(1):23-32. doi: 10.1111/j.1365-2125.1980.tb00498.x.
5
Influence of oxidation polymorphism on phenformin kinetics and dynamics.氧化多态性对苯乙双胍动力学和动态变化的影响。
Clin Pharmacol Ther. 1983 Dec;34(6):827-34. doi: 10.1038/clpt.1983.257.
6
Influence of genetic polymorphism on the metabolism and disposition of encainide in man.基因多态性对恩卡尼在人体中的代谢和处置的影响。
J Pharmacol Exp Ther. 1984 Mar;228(3):605-11.
7
Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers.
Clin Pharmacol Ther. 1981 Mar;29(3):303-9. doi: 10.1038/clpt.1981.40.
8
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.美托洛尔代谢与异喹胍氧化多态性——群体与家系研究
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
9
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.噻吗洛尔和阿替洛尔：氧化表型、药代动力学与药效学之间的关系。
Br J Clin Pharmacol. 1985 Mar;19(3):329-33. doi: 10.1111/j.1365-2125.1985.tb02651.x.
10
Prazosin: severe side effects are dose-dependent.哌唑嗪：严重副作用与剂量相关。
Br Med J. 1976 Aug 28;2(6034):508. doi: 10.1136/bmj.2.6034.508.
Zotero 插件